When a Diabetes Drug Fails: What the GLP-1 Evidence Means for Brain Health

For several years, there was cautious optimism that GLP-1 receptor agonists might also protect the aging brain. A systematic review and meta-analysis by Seminer and colleagues from the University of Galway, published in JAMA Neurology in 2025, examined 26 randomised clinical trials involving 164,531 participants. The pooled analysis found that cardioprotective glucose-lowering therapies overall were not significantly associated with a reduction in cognitive impairment or dementia, though GLP-1 receptor agonists showed a statistically significant association with reduced all-cause dementia in the subgroup analysis.

The nuance matters. A randomised controlled trial of oral semaglutide published in The Lancet in 2026 by Cummings and colleagues, involving 3,808 participants including people with significant small vessel disease, showed zero efficacy in slowing cognitive decline. This population overlaps directly with vascular cognitive impairment, the condition ReCOGnAIze is designed to detect.

The message is not that nothing works. It is that pharmacological approaches have produced mixed results, and the evidence base is shifting toward early detection combined with multimodal, non-pharmacological intervention. A review of molecular biomarkers for vascular cognitive impairment by Hosoki and colleagues, published in Nature Reviews Neurology in 2023, identified the key pathophysiological processes underlying vascular brain injury: atherosclerosis, endothelial dysfunction, and blood-brain barrier breakdown. Specificity matters for treatment. A patient with vascular cognitive impairment requires a different intervention approach than someone on the Alzheimer's pathological continuum.

If you or a family member has been diagnosed with vascular risk factors or mild cognitive changes, speak to your doctor about a structured monitoring and intervention plan.